Clinical Trials

Jacob P. Lalezari, MD, at Quest Clinical to lead next trial of new immunotherapy

Published in AIDS Weekly, December 26th, 2005

CytoDyn, Inc., (CYDY) has tapped Jacob P. Lalezari, MD at Quest Clinical Research in San Francisco, California, as principal investigator for the next study of Cytolin, a targeted immune therapy for HIV/AIDS, pending U.S. Food & Drug Administration approval.

Quest Clinical Research has conducted clinical trials for Merck, Bayer, Pfizer, and Roche, among others.

Lalezari is an assistant clinical professor of medicine, department of medicine, University of California at San Francisco (California). Previously, he served as codirector of the HIV Clinical Research Center at Mt. Zion Medical Center also at the University of California in San Francisco. He...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of AIDS Weekly

Source: AIDS Weekly (2005-12-26)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry